[ad_1]
BERLIN–(BUSINESS WIRE)–™E Pharma N.V. (Euronext Progress Paris: AL™E), a clinical-stage biotechnology firm targeted on growing novel therapies for remedy of most cancers by focusing on the tumor microenvironment (™E), introduced at this time that an summary that includes outcomes from the NOX-A12 GLORIA Section 1/2 trial in first-line mind most cancers (glioblastoma) has been chosen for presentation on the European Society for Medical Oncology (ESMO) Congress going down in Barcelona, Spain, September 13-17, 2024.
The oral presentation will present additional evaluation of the twin inhibition of NOX-A12 and bevacizumab in glioblastoma within the enlargement arm of the GLORIA Section 1/2 trial. The complete summary will probably be printed on-line through the ESMO Congress web site. 00:05 a.m. CEST on Monday, September 09, 2024. It is going to be accessible concurrently on the ™E Pharma web site.
Twin inhibition of postradiogenic angio-vasculogenesis in glioblastoma: Outcomes of the section 1/2 GLORIA trialPresenter: Dr. Frank A. Giordano, Chair of the Division of Radiation Oncology, College Medical Middle Mannheim, GermanySession: Mini oral session: CNS tumorsTime and Date: 08.30-8.35 a.m. CEST, Sunday, September 15, 2024
About ™E Pharma
™E Pharma is a clinical-stage firm targeted on growing novel therapies for remedy of probably the most aggressive cancers. The corporate’s oncology-focused pipeline is designed to behave on the tumor microenvironment (™E) and the most cancers immunity cycle by breaking tumor safety obstacles in opposition to the immune system and blocking tumor restore.
View supply model on businesswire.com: https://www.businesswire.com/information/residence/20240716299422/en/
For extra data:™E Pharma N.V.Aram Mangasarian, Ph.D., CEOTel. +49 (0) 30 16637082 0investors@tmepharma.com
Investor and Media Relations:LifeSci AdvisorsGuillaume van RenterghemTel. +41 (0) 76 735 01 31gvanrenterghem@lifesciadvisors.com
NewCapArthur RouilléTel. +33 (0) 1 44 71 00 15arouille@newcap.fr
Supply: ™E Pharma N.V.
[ad_2]
Source link
